Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
levophencynonate hydrochloride
- Development stage
- Phase 2
- Lead developer
- Sihuan Pharmaceutical
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Administration
- Oral[3]
01
Overview
Levophencynonate hydrochloride is the active enantiomer of phencynonate and acts as an anticholinergic agent with muscarinic receptor antagonist properties. It competitively binds to central muscarinic acetylcholine receptors (notably M4 subtype), thereby inhibiting cholinergic neurotransmission in the central nervous system. This mechanism underlies its efficacy in preventing acute motion sickness and vertigo with a profile similar to scopolamine. Levophencynonate has been investigated for use in vertigo (especially due to posterior circulation infarction), motion sickness prevention, and Parkinson's disease. The drug was developed by Sihuan Pharmaceutical Holdings Group and originated from the Academy of Military Medical Sciences[1][2][3][5][8].
- Brand names
- LH tablet
- Other names
- levophencynonatelevo-phencynonate(L)-phencynonate hydrochlorideL-hydrochloric acid phencynonateL-phencynonate hydrochloric
02
Targets
CHRM4 (M4)
Beyond the preview
Go deeper on levophencynonate hydrochloride.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on levophencynonate hydrochloride.